• 45th Annual Raymond James Institutional Investors Conference

    03/04/2024 | 4:35pm EST

  • TD Cowen 44th Annual Health Care Conference

    03/05/2024 | 12:50pm EST

Events & Presentations

  • TD Cowen 44th Annual Health Care Conference

    03/05/2024 | 9:50am PST / 12:50pm EST

  • 45th Annual Raymond James Institutional Investors Conference

    03/04/2024 | 1:35pm PST / 4:35pm EST

  • Myriad Genetics Fourth Quarter 2023 Financial Earnings

    02/27/2024 | 1:30pm PST / 4:30pm EST

Financial Reports and Filings

Date Filing Title Downloads
03/18/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/18/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/18/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/18/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/18/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/18/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/18/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/18/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/18/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/18/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL

Latest News

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance Thumbnail

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

Feb 27, 2024 | Financial | Corporate

Read more
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 Thumbnail

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Feb 27, 2024 | Products

Read more
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 Thumbnail

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Feb 21, 2024 | Financial | Corporate

Read more

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics